Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Five Prime Therapeutics Inc's Business Segments
Five Prime Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Annual Results
Revenue by Product & Service Category -
- Collaboration62.1%
- License37.9%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration | $ 8 | 62.1% |
| License | $ 5 | 37.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Five Prime Therapeutics Inc
Five Prime Therapeutics Inc. is a clinical-stage biotechnology company that specializes in discovering and developing innovative protein therapeutics. Based in South San Francisco, California, the company focuses on using its proprietary discovery platform to identify novel targets and develop therapeutics that improve the lives of patients suffering from serious diseases.
The foundation of Five Prime's unique discovery platform lies in their comprehensive library of more than 10,000 human extracellular proteins. By using this library, they are able to identify potential therapeutic targets that could be used to develop new drugs. The company's discovery platform is also based on their expertise in protein science, protein bioinformatics, and translational research.
One of the key areas of focus for Five Prime is oncology, specifically in developing targeted therapies for solid tumors. Their lead product candidate, bemarituzumab, is a first-in-class antibody therapy that targets FGFR2b, a receptor found in multiple solid tumor types. Bemarituzumab is currently being evaluated in a Phase 3 clinical trial for the treatment of gastric and gastroesophageal junction cancer.
In addition to oncology, Five Prime is involved in other therapeutic areas, including immuno-oncology, fibrosis, and immuno-inflammatory diseases. The company has a number of other programs in its pipeline, such as FPT155, a potential CD80-Fc fusion protein for immuno-oncology, and FPT155-002, a Phase 1 study evaluating FPT155 in combination with pembrolizumab in patients with advanced solid tumors.
Five Prime also collaborates with pharmaceutical and biotechnology partners to develop its therapeutics. For example, they have a strategic collaboration with Bristol Myers Squibb (BMS) to evaluate the combination of bemarituzumab and Opdivo (nivolumab) in multiple tumor types. This partnership aims to leverage the complementary mechanisms of the two drugs to enhance the antitumor immune response and potentially improve patient outcomes.
Furthermore, Five Prime has a strong focus on translational research and biomarker identification to guide its clinical development efforts. By identifying specific biomarkers, the company aims to identify patient subgroups that are most likely to benefit from their therapies. This personalized medicine approach could potentially improve treatment response rates and minimize side effects.
Overall, Five Prime Therapeutics Inc. is a dynamic biotechnology company with a strong emphasis on discovering and developing innovative protein therapeutics. With a robust pipeline of candidates and strategic collaborations in place, they are well-positioned to make significant contributions to the field of precision medicine and improve patient outcomes in various disease areas.
The foundation of Five Prime's unique discovery platform lies in their comprehensive library of more than 10,000 human extracellular proteins. By using this library, they are able to identify potential therapeutic targets that could be used to develop new drugs. The company's discovery platform is also based on their expertise in protein science, protein bioinformatics, and translational research.
One of the key areas of focus for Five Prime is oncology, specifically in developing targeted therapies for solid tumors. Their lead product candidate, bemarituzumab, is a first-in-class antibody therapy that targets FGFR2b, a receptor found in multiple solid tumor types. Bemarituzumab is currently being evaluated in a Phase 3 clinical trial for the treatment of gastric and gastroesophageal junction cancer.
In addition to oncology, Five Prime is involved in other therapeutic areas, including immuno-oncology, fibrosis, and immuno-inflammatory diseases. The company has a number of other programs in its pipeline, such as FPT155, a potential CD80-Fc fusion protein for immuno-oncology, and FPT155-002, a Phase 1 study evaluating FPT155 in combination with pembrolizumab in patients with advanced solid tumors.
Five Prime also collaborates with pharmaceutical and biotechnology partners to develop its therapeutics. For example, they have a strategic collaboration with Bristol Myers Squibb (BMS) to evaluate the combination of bemarituzumab and Opdivo (nivolumab) in multiple tumor types. This partnership aims to leverage the complementary mechanisms of the two drugs to enhance the antitumor immune response and potentially improve patient outcomes.
Furthermore, Five Prime has a strong focus on translational research and biomarker identification to guide its clinical development efforts. By identifying specific biomarkers, the company aims to identify patient subgroups that are most likely to benefit from their therapies. This personalized medicine approach could potentially improve treatment response rates and minimize side effects.
Overall, Five Prime Therapeutics Inc. is a dynamic biotechnology company with a strong emphasis on discovering and developing innovative protein therapeutics. With a robust pipeline of candidates and strategic collaborations in place, they are well-positioned to make significant contributions to the field of precision medicine and improve patient outcomes in various disease areas.
Five Prime Therapeutics, Inc. is a biotechnology company specialized in discovering and developing innovative medicines for cancer and other diseases. Below is an extensive overview of the segments, products, and services that Five Prime Therapeutics offers.
Segments
Five Prime operates primarily within the biopharmaceutical sector with a focus on oncology. Its segments encompass drug discovery, clinical development, and commercialization strategies, aiming to develop targeted therapies that harness the body’s immune system or directly inhibit tumor growth while minimizing adverse effects.
Product Pipeline
Five Prime Therapeutics has a diverse pipeline of candidates undergoing various phases of development, primarily focusing on protein therapeutics and biologics. The main areas of focus include:
1. Immuno-Oncology:
Five Prime is heavily invested in immunotherapy, utilizing the bodys immune mechanisms to combat cancer.
- Checkpoint Inhibitors: These products target immune checkpoints, enhancing the immune systems ability to recognize and destroy cancer cells.
- T Cell Engagers: These are designed to link T cells with cancer cells, promoting a targeted immune response.
2. Targeted Therapies:
This involves the development of drugs tailored to specific genetic mutations or molecular targets within the cancer cells.
- Inhibitors of Growth Factor Receptors: These products are aimed at blocking signals that promote tumor growth and survival.
3. Combination Therapies:
Five Prime explores synergistic effects when combining multiple therapeutic agents, enhancing treatment efficacy and improving patient outcomes.
Notable Products
Five Prime has several advanced therapy candidates and initiatives in its pipeline:
- Avapritinib: Although originally developed for gastrointestinal stromal tumors (GISTs), this receptor tyrosine kinase inhibitor is part of their portfolio focusing on targeted treatments for other malignancies too.
- FP-1039/FPA-008: This investigational therapeutic is a protein designed to inhibit the activity of growth factors that are often associated with tumor proliferation.
Research Collaborations
Five Prime actively engages in strategic collaborations with other biopharmaceutical companies and academic institutions to enhance its research capabilities and bring novel therapeutics to market more efficiently. These partnerships may involve shared insights on drug mechanisms, pooling resources for clinical trials, or combining technologies to develop multi-modal treatment strategies.
Services Offered
Beyond its research and development efforts, Five Prime also offers various services related to its core competencies:
- Drug Development Expertise: Pharmaceutical companies may engage Five Prime for its expertise in navigating the drug development process, from preclinical research through post-marketing studies.
- Preclinical and Clinical Trial Management: Five Prime assists partners with managing trials, ensuring compliance with regulatory requirements, and leveraging its infrastructure for efficient study execution.
- Biomarker Development: To complement its therapeutic development, the company may focus on biomarker discovery, helping to identify patient populations that could benefit the most from its therapies.
Conclusion
Five Prime Therapeutics represents a dynamic entity within the biotechnology landscape, utilizing cutting-edge science to forge advancements in oncology treatment. With a pipeline enriched with innovative therapies and a commitment to research partnerships, Five Prime aims to redefine cancer care by creating targeted, effective, and patient-centered treatment modalities. The companys overarching goal remains clear: to transform the standard of care for patients suffering from cancer and associated diseases, thereby improving overall patient outcomes and life quality.
Segments
Five Prime operates primarily within the biopharmaceutical sector with a focus on oncology. Its segments encompass drug discovery, clinical development, and commercialization strategies, aiming to develop targeted therapies that harness the body’s immune system or directly inhibit tumor growth while minimizing adverse effects.
Product Pipeline
Five Prime Therapeutics has a diverse pipeline of candidates undergoing various phases of development, primarily focusing on protein therapeutics and biologics. The main areas of focus include:
1. Immuno-Oncology:
Five Prime is heavily invested in immunotherapy, utilizing the bodys immune mechanisms to combat cancer.
- Checkpoint Inhibitors: These products target immune checkpoints, enhancing the immune systems ability to recognize and destroy cancer cells.
- T Cell Engagers: These are designed to link T cells with cancer cells, promoting a targeted immune response.
2. Targeted Therapies:
This involves the development of drugs tailored to specific genetic mutations or molecular targets within the cancer cells.
- Inhibitors of Growth Factor Receptors: These products are aimed at blocking signals that promote tumor growth and survival.
3. Combination Therapies:
Five Prime explores synergistic effects when combining multiple therapeutic agents, enhancing treatment efficacy and improving patient outcomes.
Notable Products
Five Prime has several advanced therapy candidates and initiatives in its pipeline:
- Avapritinib: Although originally developed for gastrointestinal stromal tumors (GISTs), this receptor tyrosine kinase inhibitor is part of their portfolio focusing on targeted treatments for other malignancies too.
- FP-1039/FPA-008: This investigational therapeutic is a protein designed to inhibit the activity of growth factors that are often associated with tumor proliferation.
Research Collaborations
Five Prime actively engages in strategic collaborations with other biopharmaceutical companies and academic institutions to enhance its research capabilities and bring novel therapeutics to market more efficiently. These partnerships may involve shared insights on drug mechanisms, pooling resources for clinical trials, or combining technologies to develop multi-modal treatment strategies.
Services Offered
Beyond its research and development efforts, Five Prime also offers various services related to its core competencies:
- Drug Development Expertise: Pharmaceutical companies may engage Five Prime for its expertise in navigating the drug development process, from preclinical research through post-marketing studies.
- Preclinical and Clinical Trial Management: Five Prime assists partners with managing trials, ensuring compliance with regulatory requirements, and leveraging its infrastructure for efficient study execution.
- Biomarker Development: To complement its therapeutic development, the company may focus on biomarker discovery, helping to identify patient populations that could benefit the most from its therapies.
Conclusion
Five Prime Therapeutics represents a dynamic entity within the biotechnology landscape, utilizing cutting-edge science to forge advancements in oncology treatment. With a pipeline enriched with innovative therapies and a commitment to research partnerships, Five Prime aims to redefine cancer care by creating targeted, effective, and patient-centered treatment modalities. The companys overarching goal remains clear: to transform the standard of care for patients suffering from cancer and associated diseases, thereby improving overall patient outcomes and life quality.